Encorafenib plus binimetinib yields high confirmed objective response rates (75% in treatment-naïve; 46% in previously treated) in BRAF V600E-mutant metastatic NSCLC.
Updated median overall survival (mOS) reaches 47.6 months in treatment-naïve patients, representing the longest mOS reported with targeted therapy in this population.
The combination’s safety profile is consistent, with manageable adverse events predominantly comprising gastrointestinal symptoms and fatigue.
Durable responses and prolonged progression-free survival (PFS) underscore the efficacy of dual BRAF/MEK inhibition, supporting its FDA-approved use in this subset of NSCLC patients.
